Antibiotic susceptibility data

Tables 3 and 4 present antibiotic susceptibility data for A. calcoaceticus/baumannii and A. lwoffii, respectively.

Table 3. Antibiotic susceptibility data for reports of A. calcoaceticus/baumannii bacteraemia, England, Wales, and Northern Ireland: 2004 to 2008*

	A. calcoaceticus/baumannii	2004	2005	2006	2007	2008
	Total reports	374	400	413	415	295
Gentamicin	% Non-susceptible	26%	23%	26%	21%	20%
	Reports with susceptibility data	285	276	313	345	253
Amikacin	% Non-susceptible	16%	21%	26%	22%	24%
	Reports with susceptibility data	91	115	187	211	160
Tobramycin	% Non-susceptible	14%	23%	25%	30%	18%
	Reports with susceptibility data	50	71	93	121	100
Ciprofloxacin	% Non-susceptible	36%	30%	36%	31%	29%
	Reports with susceptibility data	266	269	319	338	243
Imipenem	% Non-susceptible	5%	9%	21%	26%	30%
	Reports with susceptibility data	73	94	126	183	108
Meropenem	% Non-susceptible	13%	20%	35%	24%	29%
	Reports with susceptibility data	128	126	175	186	159
Cefotaxime	% Non-susceptible	86%	74%	88%	82%	89%
	Reports with susceptibility data	156	165	206	193	148
Ceftazidime	% Non-susceptible	69%	71%	70%	68%	72%
	Reports with susceptibility data	191	171	233	272	185

* Data extracted 27th October 2009

For A. calcoaceticus/baumannii, the only statistically significant changes in susceptibility (measured by chi-square test for trend and controlling for inter-laboratory variation), from 2004 to 2008, were observed for imipenem (5% to 30%; P< 0.025), and meropenem (13% to 29%; P<0.0001). There were no statistically significant trends for gentamicin (20%), amikacin (24%), tobramycin (18%), ciprofloxacin (29%), cefotaxime (89%) or ceftazidime (72%).

Table 4 Antibiotic susceptibility data for reports of A. lwoffii bacteraemia, England, Wales, and Northern Ireland: 2004 to 2008*

	A.Iwoffii	2004	2005	2006	2007	2008
	Total reports	224	223	246	309	273
Gentamicin	% Non-susceptible	1%	1%	5%	4%	2%
	Reports with susceptibility data	150	154	191	247	229
Amikacin	% Non-susceptible	5%	0%	2%	2%	0%
	Reports with susceptibility data	44	54	87	130	113
Tobramycin	% Non-susceptible	0%	0%	10%	6%	2%
	Reports with susceptibility data	27	25	29	48	58
Ciprofloxacin	% Non-susceptible	5%	5%	6%	5%	3%
	Reports with susceptibility data	144	151	190	236	193
Imipenem	% Non-susceptible	0%	0%	4%	0%	3%
	Reports with susceptibility data	34	57	72	116	78
Meropenem	% Non-susceptible	0%	4%	4%	2%	1%
	Reports with susceptibility data	65	67	73	129	108
Cefotaxime	% Non-susceptible	20%	32%	23%	23%	26%
	Reports with susceptibility data	74	99	120	151	118
Ceftazidime	% Non-susceptible	23%	21%	13%	25%	22%
	Reports with susceptibility data	91	121	148	197	153

* Data extracted 27th October 2009

For A. lwoffii, there were no statistically signficant changes in resistance rates between 2004 and 2008 for gentamicin (2% resistant in 2008), amikacin (0%), tobramycin (2%), ciprofloxacin (3%), imipenem (3%), meropenem (1%), cefotaxime (26%), or ceftazidime (22%).

Last reviewed: 17 December 2009